Development of a cobalt(iii)-based ponatinib prodrug system-Reference-Cited by-同舟云学术

Development of a cobalt(iii)-based ponatinib prodrug system

Published:2021 Issue:10 Volume:8 Page:2468-2485
ISSN:2052-1553
Container-title:Inorganic Chemistry Frontiers
language:en
Short-container-title:Inorg. Chem. Front.

Author:

Mathuber Marlene¹²³⁴⁵,Gutmann Michael⁶⁷⁴⁵^ORCID,La Franca Mery⁶⁷⁴⁵⁸^ORCID,Vician Petra⁶⁷⁴⁵,Laemmerer Anna⁶⁷⁴⁵⁹^ORCID,Moser Patrick⁶⁷⁴⁵,Keppler Bernhard K.¹²³⁴⁵^ORCID,Berger Walter⁶⁷⁴⁵⁹^ORCID,Kowol Christian R.¹²³⁴⁵^ORCID

Affiliation:

1. Institute of Inorganic Chemistry

2. Faculty of Chemistry

3. University of Vienna

4. 1090 Vienna

5. Austria

6. Institute of Cancer Research and Comprehensive Cancer Center

7. Medical University of Vienna

8. Department of Biological

9. Research Cluster “Translational Cancer Therapy Research”

Abstract

This study presents the first hypoxia-activatable cobalt(iii) prodrugs of the clinically approved tyrosine kinase inhibitor ponatinib. The chemical properties of the complexes have been correlated with the in vivo antitumor activity.

Funder

Austrian Science Fund

Publisher

Royal Society of Chemistry (RSC)

Subject

Inorganic Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2021/QI/D1QI00211B

Reference61 articles.

1. Cell Signaling by Receptor Tyrosine Kinases

2. Mechanisms of receptor tyrosine kinase activation in cancer

3. FDA-approved small-molecule kinase inhibitors